Pure Global
NCT06410612

Block and Periarticular Injection Study

The Effect of Regional Anesthesia and Periarticular Injection and Versus Periarticular Injection Alone on Early Recovery After Total Knee Arthroplasty: A Prospective Randomized Trial
Washington University School of Medicine·Phase 4·ClinicalTrials.gov·drugEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pain, Postoperative
Drug/Device/Intervention
regional anesthesia and PAI
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Washington University School of Medicine
Location
Creve Coeur, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Mar 04, 2024
End date
Mar 01, 2025
Enrollment
200 participants
Primary outcome

Mean Visual Analog Scale (VAS) pain score for 2 weeks postoperatively

Summary

The purpose of the study is to compare two types of perioperative analgesic modalities,
 adductor canal block plus interspace between popliteal artery and capsule of the knee (IPACK)
 block and periarticular injection versus periarticular injection alone, to determine their
 relative efficacies with regard to pain relief and functional outcomes in the early
 postoperative period following primary total knee arthroplasty.

ICD-10 classifications
During surgical operationDuring surgical operationDuring surgical operationPain, unspecifiedPostoperative intestinal obstruction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06410612
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06410612 through Pure Global AI's free database. This Phase 4 trial is sponsored by Washington University School of Medicine and is currently Enrolling by invitation. The study focuses on Pain, Postoperative. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.